The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells

Haematologica

Volumn 95, Issue 7, 2010, Pages 1136-1143

  Stamatopoulos, Basile ^a   Meuleman, Nathalie ^a   de Bruyn, Cécile ^a   Delforge, Alain ^a   Bron, Dominique ^a   Lagneaux, Laurence ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Chronic lymphocytic leukemia; CXCR4; Migration; Suberoylanilide hydroxamic acid

Indexed keywords

CASPASE 3; CASPASE 6; CASPASE 8; CASPASE INHIBITOR; CHEMOKINE RECEPTOR CXCR4; FLUDARABINE PHOSPHATE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; STROMAL CELL DERIVED FACTOR 1; VORINOSTAT; ANTINEOPLASTIC AGENT; HYDROXAMIC ACID;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL MIGRATION; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIZATION; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; STROMA CELL; ANTAGONISTS AND INHIBITORS; CELL MOTION; DOWN REGULATION; DRUG EFFECTS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PATHOLOGY; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL MOVEMENT; DOWN-REGULATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RECEPTORS, CXCR4; TUMOR CELLS, CULTURED;

EID: 77953749866     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.013847     Document Type: Article

References (50)

1. Dighiero G Travade P, Chevret S, Fenaux P, Chastang C, Binet JL. B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL. Blood. 1991;78(8):1901-14.
2. Bannerji R, Byrd JC. Update on the biology of chronic lymphocytic leukemia. Curr Opin Oncol. 2000;12(1):22-9.
3. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115(3):755-64.
4. Van Bockstaele F, Verhasselt B, Philippe J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev 2009;23(1):25-47.
5. Fiamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-54.
6. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglob-ulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003; 348(18):1764-75.
7. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-7.
8. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 1996;382(6594):829-33.
9. Egawa T, Kawabata K, Kawamoto Pi, Amada K, Okamoto R, Fujii N, et al. The earliest stages of B cell development require a chemokine stromal cell-derived factor/pre-B cell growth-stimulating factor. Immunity. 2001;15(2):323-34.
10. Ma Q, Jones D, Borghesani PR Segal RA, Nagasawa T, Kishimoto T, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA. 1998,95(16):9448-53.
11. Mohle R, Failenschmid C, Bautz F, Kanz L. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived fac-tor-1 (SDF-1). Leukemia. 1999;13(12):1954-9.
12. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood. 1998; 91(7):2387-96.
13. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 1999; 94(11):3658-67.
14. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96(8):2655-63.
15. Richon VM, O'Brien JP. Histone deacety-lase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin Cancer Res. 2002;8(3):662-4.
16. Glick RD, Swendeman SL, Coffey DC, Rifkind RA, Marks PA, Richon VM, et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res. 1999;59(17):4392-9.
17. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA.2001; 98(19):10833-8.
18. He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP Jr, Rifkind RA, et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest. 2001;108(9):1321-30.
19. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008;111(3):1060-6.
20. Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, Hoshino K, Quintas-Cardama A, Richon VM, et al. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood. 2006; 108(4):1174-82.
21. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24(l):166-73.
22. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. Phase lib multicen-ter trial of vorinostat in patients with per-sistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109-15.
23. Stamatopoulos B, Meuleman N, Haibe-Kains B, Duvillier H, Massy M, Martiat P, et al. Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia. Clin Chem. 2007;53(10):1757-66.
24. Stamatopoulos B, Meuleman N, Haibe-Kains B, Saussoy P, Van Den NE, Michaux L, et al. microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood. 2009;113(21):5237-45.
25. Tondreau T, Meuleman N, Delforge A, Dejeneffe M, Leroy R, Massy M, et al. Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation; Oct4 expression, and plasticity. Stem Cells. 2005;23(8):1105-12.
26. Najar M, Rouas R, Raicevic G, Boufker HI, Lewalle P, Meuleman N, et al. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy. 2009;11(5):570-83.
27. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991; 139(2):271-9.
28. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidini-um thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162(l):156-9.
29. Ferlini C, Di Cesare S, Rainaldi G, Malorni W, Samoggia P, Biselli R, et al. Flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques. Cytometry. 1996; 24(2): 106-15.
30. Stamatopoulos B, Haibe-Kains B, Equeter C, Meuleman N, Soree A, De Bruyn C, et al. Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA. Haematologica. 2009; 94(6):790-9.
31. Bouzar AB, Boxus M, Defoiche J, Berchem G, Macallan D, Pettengell R, et al. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 2009;144(l):41-52.
32. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009; 114(20):4441-50.
33. Butler LM, Agus DB, Scher HI, Fiiggins B, Rose A, Cordon-Cardo C, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000;60(18):5165-70.
34. Huang L, Sowa Y, Sakai T, Pardee AB. Activation of the p21WAFl/CIPl promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Spl sites. Oncogene. 2000;19(50):5712-9.
35. Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIPl, but independent of p53. Oncogene. 1999; 18(50)7016-25.
36. Kim DK, Cho ES, Urn HD. Caspase-dependent and -independent events in apoptosis induced by hydrogen peroxide. Exp Cell Res. 2000;257(l):82-8.
37. Verhoven B, Krahling S, Schlegel RA, Williamson P. Regulation of phosphatidyls erine exposure and phagocytosis of apoptotic T lymphocytes. Cell Death Differ. 1999;6(3):262-70.
38. Kim R. Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer. 2005;103(8):1551-60.
39. Genini D, Adachi S, Chao Q, Rose DW, Carrera CJ, Cottam FLB, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood. 2000;96(10):3537-43.
40. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAFLA). J Biol Chem. 2003;278(14):12579-89.
41. Stamatopoulos B, Meuleman N, De Bruyn C, Mineur P, Martiat P, Bron D, et al. Antileukemic activity of valproic add in chronic lymphocytic leukemia B cells defined by microarray analysis. Leukemia. 2009; 23(12):2281-9.
42. Bokelmann I, Mahlknecht U. Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins. Mol Med. 2008;14(l-2):20-7.
43. Siitonen T, Mantymaa P, Saily M, Savolainen E, Koistinen P. Etoposide-induced apoptosis is not associated with the fas pathway in acute myeloblastic leukemia cells. Leuk Res. 2000;24(4):281-8.
44. Shao RG, Cao CX, Nieves-Neira W, Dimanche-Boitrel MT, Solary E, Pommier Y. Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. Oncogene. 2001;20(15):1852-9.
45. Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, et al. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood. 1997;90(3):935-43.
46. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-l/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 1997; 57(17):3823-9.
47. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-indudng ligand in vitro and in vivo. Cancer Res. 2000; 60(4):847-53.
48. Crazzolara R, Johrer K, Johnstone RW, Greil R, Kofler R, Meister B, et al. Fiistone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia. Br J Haematol. 2002;119(4):965-9.
49. Munk P, I, Reed J. Micro environmental interactions and survival of CLL B-cells. Leuk Lymphoma. 2004;45(12):2365-72.
50. Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 2005;106(5):1824-30.